VCM
NMRA icon

Versant Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Versant Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-421
Closed -$4.46K – 2589
2024
Q4 		$4.46K Buy
+421
New +$5.05K ﹤0.01% 1811

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Versant Capital Management's NMRA Position: Q1 2025 in Review

Versant Capital Management sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 421 shares — an estimated $4.46K sold.

Versant Capital Management first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $4.46K in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Versant Capital Management reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Versant Capital Management sold 421 Neumora Therapeutics shares in Q1 2025, an estimated $4.46K.
  • Versant Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
  • Versant Capital Management's Neumora Therapeutics position peaked at $4.46K in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Versant Capital Management's 13F filing for Q1 2025, filed 3 Apr 2025.